Objective-Studies have shown that high-density lipoprotein (HDL)-raising compounds induce regression of aortic valve stenosis (AVS) in animal models. However, whether patients with AVS have an impaired HDL metabolism is unknown. Approach and Results-A total of 1435 single nucleotide polymorphisms in genes associated with HDL cholesterol levels (in or around GALNT2, LPL, ABCA1, APOA5, SCARB1, LIPC, CETP, LCAT, LIPG, APOC4, and PLTP) were genotyped in 382 patients with echocardiography-confirmed AVS (aortic jet velocity ≥2.5 m/s) and 401 controls. After control for multiple testing, none of the genetic variants showed a positive association with case/control status (adjusted P≥0.05 for all single nucleotide polymorphisms tested). In a subsample of this cohort, HDL cholesterol levels, apolipoprotein AI levels, lecithin-cholesterol acyltransferase activity, pre-β-HDL, HDL size, and 4 parameters of cholesterol efflux capacity were measured in apolipoprotein B-depleted serum samples from 86 patients with and 86 patients without AVS. Cholesterol efflux capacity was measured using J774 macrophages with and without stimulation of ATP-binding cassette A-1 expression by cAMP, and HepG2 hepatocytes for scavenger receptor class B type 1-mediated efflux. None of these parameters were different between cases and controls. However, compared with patients without coronary artery disease, sera from patients with coronary artery disease had lower HDL cholesterol levels, scavenger receptor class B type 1-mediated efflux, and HDL size (P≤0.003), independently of the presence or absence of AVS.
A ortic valve stenosis (AVS) is a complex disorder that is present in >3% of individuals aged >75 years, and the prevalence of AVS may double within the next 50 years. 1 AVS is the most frequent indication for surgical valve replacement and for transcatheter aortic valve implantation, which remain to date the main forms of treatment for this disease. 2 Although some have suggested that the risk factors for AVS are similar to those of cardiovascular disease, studies on AVS risk factors and biomarkers are more limited than those on cardiovascular disease biomarkers. 3 Moreover, as suggested by 2 studies performed in France investigating the regional distribution of patients undergoing aortic valve replacement and the familial aggregation of the disease, AVS might have a strong genetic basis. 4, 5 Only few studies have tried to identify genetic variants or loci associated with this disease. 6, 7 To this date, genetic variants that show a consistent association with AVS risk have yet to be identified. One recent study, however, has shown that a common genetic variant at the LPA loci that is closely associated with lipoprotein(a) levels shows significant associations with aortic valve calcium content and risk of AVS in 2 European population studies. 8 Several studies have suggested that similar to coronary artery disease (CAD), high-density lipoproteins (HDLs) might have a role to play in the pathology of AVS. 9 Results from our previous investigations have suggested that HDLmimetic compounds decrease aortic valve calcium and induce February 2014 regression of AVS in animal models, 10, 11 an observation that has been confirmed recently by Speidl et al. 12 In humans, prospective epidemiological studies have shown that low levels of HDL cholesterol may be associated with the progression of aortic valvular calcium and the progression of AVS severity. 13, 14 To add support to the HDL hypothesis in AVS, additional studies testing causality of HDL in AVS are warranted. One possible approach relies on genetic epidemiology. For instance, causality can be established by showing that genetic variants associated with HDL cholesterol levels will simultaneously be associated with the risk of AVS. In the specific case of HDL, measurement of HDL functional properties could also be relevant. Recently, HDL functional properties such as their ability to remove cellular cholesterol from macrophages in vitro have been shown to be associated negatively with cardiovascular risk, independently of plasma HDL cholesterol levels. 15 However, whether this is also true for the prediction of AVS onset is not known.
The objective of the present investigation was to test the hypothesis that HDL functionality is impaired in patients with AVS, first by determining whether genetic variants that are associated with HDL cholesterol levels will also be associated with the risk of AVS in a case-control study and second by measuring cholesterol efflux capacities and HDL-related parameters, such as size, concentration, lecithin-cholesterol acyltransferase (LCAT) activity, and pre-β-HDL levels in patients with and without AVS.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Results of the Genetic Studies
The clinical characteristics of the genetic study participants of the Montreal Heart Institute (MHI) genetic cohort are shown in Table I in the online-only Data Supplement. All study participants were whites, and the majority were French Canadians. There was no sex difference between patients with or without AVS. Patients with AVS were slightly older on average and had a higher systolic blood pressure. The clinical and echocardiographic characteristics of study cases are presented in Table II in the online-only Data Supplement.
Genotyping was successful for 783 individuals (382 cases and 401 controls). The association between the 1435 single nucleotide polymorphisms (SNPs) that were genotyped and the risk of AVS is presented in Table III in the online-only Data Supplement. The majority of SNPs evaluated were not significantly associated with the risk of AVS. For SNPs nominally associated with AVS (P≤0.05), further correction for multiple testing eliminated any positive association.
To further study the association between the genetic variants associated with HDL cholesterol levels and the risk of AVS, we have assessed a weighted genetic risk score (WGRS) based on 12 SNPs previously associated with high HDL cholesterol, similar to the genetic score used by Voight et al 16 (see Table IV in the online-only Data Supplement for the SNPs included in the WGRS). Table 1 shows that the WGRS is indeed associated with HDL cholesterol levels in patients of the biomarkers study (see below; n=159). Interestingly, the HDL cholesterol WGRS was also associated with apolipoprotein (apo) AI levels, as well as total and large HDL particle concentration, but not with any metrics of cholesterol efflux. As shown in Table 2 , there were no associations between the HDL cholesterol WGRS and the risk of AVS in the MHI genetic cohort. The lack of association between the HDL WGRS and AVS was also observed in the Quebec and Paris AVS cohorts ( Table 2 ).
Results of the Biomarker Substudy
Patients of each group of the MHI cohort biomarker substudy were matched on the basis of age, sex, and the presence of CAD. With the exception of the prevalence of hypertension, which was higher in patients with AVS, there were no meaningful differences among the clinical characteristics of patients with versus without AVS. We also found that there were no differences in HDL cholesterol levels, HDL size, HDL particle concentration (of any size), apoB-depleted serum cholesterol efflux capacities, LCAT activity, and pre-β-HDL levels between patients with AVS and matched controls (Table 3) . Moreover, in patients with AVS, none of the studied parameters showed a significant association with aortic valve area (data not shown). To test the hypothesis that this absence of differences in terms of HDL parameters in patients with versus without AVS could not be attributable to our power to detect associations and given the well-established notion that HDL metabolism could be impaired in patients with CAD, we have separated the study participants based on the presence or absence of CAD. When the study population was classified on the basis of CAD, we found that CAD patients had lower HDL cholesterol levels, a smaller HDL size, a smaller amount of circulating total and large HDL particles, a lower cholesterol efflux capacity mediated by scavenger receptor class B type 1, and a higher LCAT activity compared with patients without CAD (Table 4 ). We also assessed the age and sex-adjusted correlation coefficients between cholesterol efflux capacities and parameters of HDL metabolism (Table 5 ). Overall, our results show that large HDL particles are associated more strongly with nonstimulated efflux and scavenger receptor class B type 1-mediated efflux, whereas smaller HDL particles and pre-β-HDL levels are associated with ATP-binding cassette A-1-mediated efflux.
Discussion
An increasing number of studies have documented the role of HDL and HDL-based therapies in AVS. For instance, HDL may directly interfere with the calcification process in human aortic valves. 9 In addition, our laboratory has shown previously that apoAI mimetic peptide infusions induce AVS regression in rabbit and mouse models of AVS. 10, 11 In one of our experimental studies, apoAI mimetic peptide infusions lead to significant improvements in aortic valve area and reduction in valvular calcium compared with placebo-treated rabbits. 10 Other groups have reported similar results with apoAI Milano infusions in rabbits and further demonstrated that HDL could reduce valvular and vascular calcification in vitro. 12, 17 Our objective was therefore to provide further evidence lending support to the HDL hypothesis in humans using genetic epidemiology and evaluation of HDL functionality in patients with AVS. However, our results suggest that genetic variants strongly associated with HDL cholesterol levels do not predict the risk of AVS in our case-control study. These results are in line with a recent large-scale study performed by Voight et al 16 who have shown that several genetic variants associated with HDL cholesterol levels were not associated with CAD (unlike genetic variants associated with LDL cholesterol levels), thereby questioning the potential causal role of HDL in the pathophysiology of CAD. However, in both our and Voight et al 16 studies, the investigation of genetic variants associated with measures of HDL functionality and the risk of either CAD or AVS could lead to different conclusions. However, few genetic loci associated with HDL functionality have been identified thus far. This conclusion is further supported by the fact that our weighted genetic risk score that strongly correlated with HDL cholesterol levels was not associated with any parameters of HDL cholesterol efflux capacities. Once identified, the genetic variants associated with cholesterol efflux capacities and CVD risk should be investigated to determine whether HDL cholesterol efflux capacities are actually causal in CVD and AVS. A recent study showed that older patients with AVS had a higher mean HDL particle size when compared with younger patients with AVS. 18 However, little is known about the potential differences between HDL physicochemical properties between patients with and without AVS. We have therefore measured cholesterol efflux capacities of HDL as well as nuclear magnetic resonance-measured HDL size distribution and concentration in patients with or without AVS. There again, we found no evidence of any differences between these study groups. There have been conflicting results on the impact of cholesterol efflux capacities on CAD risk. However, the results of Khera et al 15 have shown that cholesterol efflux capacities are associated negatively with CAD in a cross-sectional study. On the contrary, Li et al 19 have shown that cholesterol efflux capacities were associated with a decreased CAD risk in a cross-sectional study, but with a paradoxically increased risk of CAD in a prospective study. Both of these studies have, however, used only 1 parameter of cholesterol efflux capacities, which is equivalent to the estimation of total cholesterol efflux capacities in the present study. Although our study was not designed to specifically address this question, our results suggest that different components of cholesterol efflux capacities may be differentially associated with CAD risk. Given that we have obtained similar results in our patients with versus without CAD in terms of HDL functionality measurements compared with what has been observed in these previous crosssectional studies, we think that the absence of any differences in patients with AVS compared with those without AVS is not attributable to the small study sample but rather reflects a true negative association. However, it must be considered that aside from cholesterol efflux capacities, HDLs have other antiatherogenic properties such as their ability to inhibit oxidation of LDL particles, to improve endothelial function and to inhibit inflammation in the vascular wall. 20 These other properties of HDL were not measured in our study patients.
Calcification of vascular cells has been shown to be closely associated with increased intracellular cholesterol levels. 21 The fact that mice treated with a liver-X receptor agonist (which decreases intracellular cholesterol levels) had improved aortic valve function in hypercholesterolemic mice 22 led us to hypothesize that the ability to remove cellular cholesterol could be impaired in HDL isolated from patients with AVS, Table 5 Data are shown as mean (SD) and as n (%) for categorical variables. ABCA1 indicates ATP-binding cassette A-1; AVS, aortic valve stenosis; CAD, coronary artery disease; HDL, high-density lipoprotein; LCAT, lecithin-cholesterol acyltransferase; and SR-B1, scavenger receptor class B type 1.
. Age-and Sex-Adjusted Spearman Correlation Coefficients Showing the Association Between Cholesterol Efflux Capacities and Parameters of HDL Metabolism in the Biomarkers Study Population
*P≤0.05.
thereby suggesting that this could represent a feature of this disease. Although this hypothesis could not be confirmed, given the results of a recent report suggesting that apoAI could undergo proteolysis at the site of the aortic valve by proteases such as chymase, that HDL could increase the secretion of the anticalcifying mediator osteoprotegerin, and that it can reduce gene expression of inflammatory mediators such as TNF-α, monocyte chemoattractant protein-1, and nuclear factor-κB, the beneficial impact of circulating HDL on calcification could be independent of their capacity to promote cholesterol efflux. 9, 12 Given that there are significant differences in terms of HDL metabolism and AVS induction between animal models of AVS and humans, we think that therapies aiming at increasing the number of functional HDL particles in the bloodstream and at the site of the valve could nevertheless be beneficial for the treatment of AVS in humans.
Results of the Copenhagen City Heart Study have shown that in patients with either high or low HDL cholesterol levels, LCAT activity was lower and pre-β1-HDL levels were higher in patients with ischemic heart disease. 23 Although it was not our primary objective to investigate the role of LCAT and preβ-HDL in CAD risk prediction, our results suggest that unlike what was reported in that study, LCAT activity could be higher in patients with CAD, whereas pre-β-HDL levels are similar. Although we have used a semiquantitative method for the measurement of pre-β-HDL, levels of pre-β-HDL were positively associated with ATP-binding cassette A-1-mediated efflux and total efflux (R=0.31, P<0.0001 and R=0.21, P=0.005, respectively, for ATP-binding cassette A-1-mediated efflux and total efflux), which is similar to what has been reported in previous studies. 24 To the best of our knowledge, our study is the first to assess the relationship between cholesterol efflux capacities and indicators of HDL metabolism as assessed by nuclear magnetic resonance spectroscopic characterization of HDL subclasses distribution. We have shown that large HDL particles are associated more strongly with nonstimulated efflux and scavenger receptor class B type 1-mediated efflux, whereas smaller HDL particles are associated with ATP-binding cassette A-1-mediated efflux. With regards to LDL metabolism, it is worth mentioning that none of the parameters of LDL metabolism, such as LDL cholesterol levels, apoB levels, LDL size, and LDL particle concentrations, measured by nuclear magnetic resonance were associated with the risk of AVS (data not shown). Whether this could be because of the fact that the majority of our study patients were treated with statins (irrespective of case/control status) is unknown.
Despite our efforts to ensure that cases and controls of the genetic study only differed by the presence/absence of AVS, statistically significant differences remained between cases and controls for age and the presence of hypertension. Such differences are not unexpected given that those are known risk factors for AVS. Moreover, a selection bias may be attributable to the fact that controls underwent an echocardiogram, which may be indicative of a certain disease state. However, we think that this aspect of our study design increased the likelihood of having a high-quality phenotype. In addition, we found that there was marked heterogeneity among controls with regard to the indication to undergo echocardiography, the most important reason being previous myocardial infarction, with only ≈15% of controls being referred to echocardiography because of that reason. Considering the study design and prevalence of the phenotype in the population, at a minor allele frequency of 0.20, power calculations suggested that we had 80% of detecting an odds ratio of 1.80 at an α of 0.001 in the MHI genetic cohort. Despite the fact that the lack of association between HDL cholesterol-related genetic variants and AVS was also confirmed in 2 additional patient cohorts, it should be noted that the controls selected for these additional studies did not undergo echocardiography. Nevertheless, because of our limited sample size, we think that our statistical power may not have been optimal, making a definitive conclusion about lack of association, particularly with the genetics associations, difficult.
Conclusions
The objective of this study was to confirm the role of HDL in the pathophysiology of AVS using genetic epidemiology and evaluation of HDL functionality in patients with AVS. The results suggest that HDL-associated genetic variants and HDL functional properties, such as cholesterol efflux capacities, do not seem to influence AVS susceptibility. We also highlight some differences between the pathogenesis of CAD versus AVS, as HDL functional characteristics are impaired in patients with CAD but not in those with AVS. Nevertheless, whether HDL-based therapies could reduce AVS progression in humans, as it does in animals, remains a hypothesis worth testing.
There is increasing evidence supporting a role for high-density lipoproteins (HDL) in the pathophysiology of aortic valve stenosis (AVS). For instance, we and others have shown that HDL infusions may induce AVS regression in animal models of AVS. However, whether patients with AVS have an impaired HDL metabolism is unknown. The results of our study show for the first time that genetic variants associated with HDL cholesterol levels were not associated with the risk of AVS. Also, none of the studied biomarkers of HDL metabolism that we have assessed (HDL size, concentration, pre-β-HDL levels, cholesterol efflux capacities, and LCAT activity) were associated with the presence of AVS. However, we report that many of the biomarkers of HDL functionality were impaired in patients with coronary artery disease, irrespective of the presence or absence of AVS, thereby highlighting important differences in the pathogenesis of CAD and AVS.
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